Introduction
============

While there have been many criteria for determining the prognosis of patients with malignant tumors, such as the TNM staging criteria, these serve only to provide physicians with information regarding the outcome of patients during daily clinical analysis. In a previous study, we demonstrated that the Pathological Prognostic Score (PPS), determined based on histopatological data including depth of tumor, lymph node metastasis, lymphatic invasion and venous invasion, clearly classified the prognosis of patients with colorectal carcinoma ([@b1-ol-05-03-0978]).

Although undifferentiated carcinoma of the colon and rectum have been reputed to possess a more aggressive potential, which leads to a worse prognosis of patients ([@b2-ol-05-03-0978]), the criteria for determining the prognosis of patients with colorectal carcinoma reflected by this pathological type of tumor has not yet been presented. In this study, we investigated the significance of a novel staging criterion (a five-point scoring system; FPSS) for determining the prognosis of patients with colorectal carcinoma. The FPSS comprised five histopathological categories of patients with colorectal carcinoma: Depth of tumor, lymph node metastasis, lymphatic invasion, venous invasion and histopathological tumor type.

Patients and methods
====================

Patients
--------

In total, 357 patients with colorectal carcinoma, who had been treated by surgical resection at the Fukuoka Higashi Medical Center from January 1997 to January 2011, were evaluated. Forty-two patients had been treated with palliative resection due to the presence of distant metastasis and/or peritoneal dissemination. No patients had been treated with neoadjuvant therapy. Patients were aged between 24 and 91 years (mean, 69) and the group comprised 214 males and 143 females. The study was approved by the Ethics Committee of Fukuoka Higashi Medical Center, Koga, Japan. Written infomed consent was obtained from the patient.

Pathological research
---------------------

The clinicopathological factors were determined according to the general rules for clinical and pathological studies on cancer of the colon, rectum and anus, outlined by the Japanese Research Society for Cancer of the Colon and Rectum ([@b3-ol-05-03-0978]). Additionally, TNM tumor stages were determined by the TNM classification of malignant tumors prescribed by the International Union Against Cancer ([@b4-ol-05-03-0978]).

FPSS
----

FPSS scores were determined by assigning one point to a more advanced result in each of the following categories: Tumor depth (T1 and 2 vs. T3 and 4); lymph node metastasis (positive vs. negative); lymphatic invasion (positive vs. negative); venous invasion (positive vs. negative) and histopathological tumor type (differentiated vs. undifferentiated tumor). Subsequently, FPSS scores were determined by an aggregate of points for each category and ranged from 0--5.

Patient follow-up
-----------------

Follow-up of patients was continued until mortality and only patients whose cause of death was colorectal carcinoma were included in the tumor-related deaths. The time period between surgery and death was termed the survival time.

Statistical analysis
--------------------

All statistical analyses were conducted using StatView version 5.0 (SAS Institute Inc, Cary, NC, USA). Then, a χ^2^ test was used to compare the difference in proportion values between FPSS scores. A Mann-Whitney U test was used to compare the mean ages of patients. Survival curves were conducted using the Kaplan-Meier method and a Mantel-Cox test was used to analyze their equality. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Each factor included in the FPSS (tumor depth, nodal metastasis, lymphatic invasion, venous invasion and histopathological tumor type) was found to be an indicator of worse prognosis in patients with colorectal carcinoma ([Table I](#t1-ol-05-03-0978){ref-type="table"}).

The study population was divided into three groups according to the FPSS score: 0 and 1 (153 patients, 42.9%); 2 and 3 (150 patients, 42.0%); and 4 and 5 (54 patients, 15.1%). A significant correlation was observed between FPSS score and the following tumor-related factors: Tumor depth, lymph node (nodal) metastasis, lymphatic invasion, venous invasion and proportion of curative resection (P\<0.0001 for each factor; [Table II](#t2-ol-05-03-0978){ref-type="table"}).

The 1-, 3- and 5-year survival rates of patients with FPSS scores of 0 and 1 were 99.3, 97.4 and 96.2%, respectively. The rates were 95.5, 87.1 and 80.5%, respectively, in patients with FPSS scores of 2 and 3; and 83.8, 54.7 and 35.8%, respectively, in patients with FPSS scores of 4 and 5. A statistically significant difference was observed between the survival of patients with FPSS scores of 0 and 1, and 2 and 3 (P= 0.0002); as well as FPSS scores of 2 and 3, and 4 and 5 (P\<0.0001; [Fig. 1](#f1-ol-05-03-0978){ref-type="fig"}).

Subsequently, an investigation restricted to 315 patients who had been treated with curative resection was performed. Similarly, a significant correlation was observed between FPSS scores and certain investigated tumor-related factors ([Table III](#t3-ol-05-03-0978){ref-type="table"}). The 1-, 3- and 5-year survival rates of patients with FPSS scores of 0 and 1 were 99.3, 97.4 and 96.2%, respectively. Such rates were 98.2, 93.6 and 85.8%, respectively, in patients with FPSS scores of 2 and 3; and 97.2, 67.7 and 51.3%, respectively, in patients with FPSS scores of 4 and 5. Additionally, a significant difference was observed between survival of patients with FPSS scores of 0 and 1, and 2 and 3 (P= 0.016); and FPSS scores of 2 and 3, and 4 and 5 (P\<0.0001; [Fig. 2](#f2-ol-05-03-0978){ref-type="fig"}).

Discussion
==========

We have previously demonstrated the prognostic significance of the Pathologic Prognostic Score (PPS), determined by pathological tumor-related factors including depth of the tumor, lymph node metastasis, lymphatic invasion and venous invasion, which has provided a useful prognostic stratification for patients with gastric carcinoma ([@b5-ol-05-03-0978]) and colorectal carcinoma ([@b1-ol-05-03-0978]).

Poorly differentiated or undifferentiated carcinoma, including poorly differentiated adenocarcinoma and mucinous carcinoma of the colon and rectum, has been reported to possess a more aggressive biological potential compared with differentiated carcinomas ([@b2-ol-05-03-0978],[@b6-ol-05-03-0978]--[@b9-ol-05-03-0978]). Certain clinical and experimental studies have been conducted to identify the subtype among colorectal poorly differentiated carcinoma that has a more progressive potential or causes a more unfavorable prognosis of patients ([@b10-ol-05-03-0978]--[@b13-ol-05-03-0978]). However, to the best of our knowledge, there have been no studies regarding a criterion for determining the tumor stage of poorly differentiated or undifferentiated colon and rectal carcinoma.

Therefore, we set out to create an evolved criterion, FPSS, based on data regarding the histopathological tumor type, separating poorly differentiated and differentiated carcinoma, in addition to PPS, to potentially determine the prognosis of patients with colorectal carcinoma. A significant difference in prognosis was found between patients who had FPSS scores of 0 and 1, and 2 and 3; and FPSS scores of 2 and 3, and 4 and 5. Therefore, there is evidence to suggest that the quality of stratification observed in the classification system was useful. Moreover, an analysis of patients who had been treated with curative resection demonstrated similar results.

As emphasized in previous studies, a novel criterion for determining the prognosis of cancer patients has the potential for simple and useful application ([@b1-ol-05-03-0978],[@b5-ol-05-03-0978],[@b14-ol-05-03-0978]). While the five histopathological tumor-related factors comprising the FPSS are relatively common and the majority of medical institutes are capable of examining them, surgeons would benefit from the convenience of the clinical application of the FPSS in treating patients with colorectal carcinoma. This is due to the fact that the FPSS provides useful information regarding the clinical outcomes of patients. In conclusion, the FPSS may be a useful criteria for predicting the clinical outcome of patients with colorectal carcinoma.

![Survival curves. Dotted line, FPSS scores of 0 and 1; thin line, FPSS scores of 2 and 3; thick line, FPSS scores of 4 and 5. FPSS; five-point scoring system.](OL-05-03-0978-g00){#f1-ol-05-03-0978}

![Survival curves for patients who had been treated with curative resection. Dotted line, FPSS scores of 0 and 1; thin line, FPSS scores of 2 and 3; thick line, FPSS scores of 4 and 5. FPSS; five-point scoring system.](OL-05-03-0978-g01){#f2-ol-05-03-0978}

###### 

Analysis of survival rates based on five pathological factors.

  Characteristic       No. of patients   5-year SR (%)   P-value
  -------------------- ----------------- --------------- ----------
  Depth of tumor                                         
    T1 and T2          106               98.7            \<0.0001
    T3 and T4          251               74.5            
  Nodal metastasis                                       
    No                 205               91.4            \<0.0001
    Yes                152               68.3            
  Lymphatic invasion                                     
    No                 214               91.4            \<0.0001
    Yes                143               67.1            
  Venous invasion                                        
    No                 259               88.5            \<0.0001
    Yes                98                63.2            
  Histologic type                                        
    Differentiated     325               86.3            \<0.0001
    Undifferentiated   32                37.5            

SR, survival rate.

###### 

Correlation between FPSS score and clinicopathological characteristics of patients.

                       No. of patients (%)                            
  -------------------- --------------------- ------------ ----------- ----------
  Gender                                                              
    Male               95 (62.1)             92 (61.3)    27 (50.0)   0.267
    Female             58 (37.9)             58 (38.7)    27 (50.0)   
  Age (years ± SD)     69.6±10.7             69.8±10.9    68.8±12.1   0.906
  Location of tumor                                                   
    Colon              108 (70.6)            106 (70.7)   38 (70.4)   0.999
    Rectum             45 (29.4)             44 (29.3)    16 (29.6)   
  Depth of tumor                                                      
    T1                 46 (30.1)             0            0           \<0.0001
    T2                 52 (34.0)             8 (5.3)      0           
    T3                 55 (35.9)             134 (89.4)   52 (96.3)   
    T4                 0                     8 (5.3)      2 (3.7)     
  Nodal metastasis                                                    
    No                 147 (96.1)            55 (36.7)    3 (5.6)     \<0.0001
    Yes                6 (3.9)               95 (63.3)    51 (94.4)   
  Lymphatic invasion                                                  
    No                 146 (95.4)            67 (44.7)    1 (1.9)     \<0.0001
    Yes                7 (4.6)               83 (55.3)    53 (98.1)   
  Venous invasion                                                     
    No                 144 (94.1)            107 (71.3)   8 (14.8)    \<0.0001
    Yes                9 (5.9)               43 (28.7)    46 (85.2)   
  Resection                                                           
    Curative           152 (99.3)            126 (84.0)   37 (68.5)   \<0.0001
    Non-curative       1 (0.7)               24 (16.0)    17 (31.5)   

FPSS, five-point scoring system.

###### 

Correlation between FPSS score and clinicopathological characteristics of patients treated with curative resection.

                       No. of patients (%)                            
  -------------------- --------------------- ------------ ----------- ----------
  Gender                                                              
    Male               95 (62.5)             79 (62.7)    19 (51.4)   0.419
    Female             57 (37.5)             47 (37.3)    18 (48.6)   
  Age (years ± SD)     69.6±10.8             70.2±11.0    71.8±10.9   0.268
  Location of tumor                                                   
    Colon              108 (71.1)            92 (73.0)    24 (64.9)   0.630
    Rectum             44 (28.9)             34 (27.0)    13 (35.1)   
  Depth of tumor                                                      
    T1                 46 (30.3)             0            0           \<0.0001
    T2                 52 (34.2)             6 (4.8)      0           
    T3                 54 (35.5)             114 (90.4)   35 (94.6)   
    T4                 0                     6 (4.8)      2 (5.4)     
  Nodal metastasis                                                    
    No                 146 (96.1)            48 (38.1)    3 (8.1)     \<0.0001
    Yes                6 (3.9)               78 (61.9)    34 (91.9)   
  Lymphatic invasion                                                  
    No                 145 (95.4)            56 (44.4)    1 (2.7)     \<0.0001
    Yes                7 (4.6)               70 (55.6)    36 (97.3)   
  Venous invasion                                                     
    No                 143 (94.1)            93 (73.8)    4 (10.8)    \<0.0001
    Yes                9 (5.9)               33 (26.2)    33 (89.2)   

FPSS, five-point scoring system.
